1
|
Edmunds AJF, Muehlebach M, Jung PM, Hueter OF, Stoller A, Jeanguenat A, Emery D, Sikervar V, Sen I, Rendler S, Buchholz A. Alkyl sulfones: discovery of novel structural types with differentiated opportunities for insect control. PEST MANAGEMENT SCIENCE 2024. [PMID: 39023381 DOI: 10.1002/ps.8320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/16/2024] [Revised: 06/21/2024] [Accepted: 07/05/2024] [Indexed: 07/20/2024]
Abstract
The discovery of novel chemical classes with novel modes of action for insect control form the backbone of innovation with the goal to deliver much-needed solutions into the hands of growers. Over the last decade, alkyl sulfones have emerged as one of the most versatile new classes and are under intensive investigation in many R&D programs in the industry, with Sumitomo Chemicals recently introducing oxazosulfyl as a first active ingredient to the market. In this review, we discuss some of our strategies to invent novel classes based upon ligand-based design, and also show how incorporation of physical chemical properties into our design enabled us to predictably control chewing and sucking pests. © 2024 Society of Chemical Industry.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Vikas Sikervar
- Jealott's Hill International Research Centre, Bracknell, UK
| | - Indira Sen
- Syngenta Biosciences Pvt Ltd, Corlim, India
| | | | | |
Collapse
|
2
|
Juza R, Musilek K, Mezeiova E, Soukup O, Korabecny J. Recent advances in dopamine D 2 receptor ligands in the treatment of neuropsychiatric disorders. Med Res Rev 2023; 43:55-211. [PMID: 36111795 DOI: 10.1002/med.21923] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2021] [Revised: 07/29/2022] [Accepted: 08/09/2022] [Indexed: 02/04/2023]
Abstract
Dopamine is a biologically active amine synthesized in the central and peripheral nervous system. This biogenic monoamine acts by activating five types of dopamine receptors (D1-5 Rs), which belong to the G protein-coupled receptor family. Antagonists and partial agonists of D2 Rs are used to treat schizophrenia, Parkinson's disease, depression, and anxiety. The typical pharmacophore with high D2 R affinity comprises four main areas, namely aromatic moiety, cyclic amine, central linker and aromatic/heteroaromatic lipophilic fragment. From the literature reviewed herein, we can conclude that 4-(2,3-dichlorophenyl), 4-(2-methoxyphenyl)-, 4-(benzo[b]thiophen-4-yl)-1-substituted piperazine, and 4-(6-fluorobenzo[d]isoxazol-3-yl)piperidine moieties are critical for high D2 R affinity. Four to six atoms chains are optimal for D2 R affinity with 4-butoxyl as the most pronounced one. The bicyclic aromatic/heteroaromatic systems are most frequently occurring as lipophilic appendages to retain high D2 R affinity. In this review, we provide a thorough overview of the therapeutic potential of D2 R modulators in the treatment of the aforementioned disorders. In addition, this review summarizes current knowledge about these diseases, with a focus on the dopaminergic pathway underlying these pathologies. Major attention is paid to the structure, function, and pharmacology of novel D2 R ligands, which have been developed in the last decade (2010-2021), and belong to the 1,4-disubstituted aromatic cyclic amine group. Due to the abundance of data, allosteric D2 R ligands and D2 R modulators from patents are not discussed in this review.
Collapse
Affiliation(s)
- Radomir Juza
- Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic.,Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
| | - Kamil Musilek
- Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic.,Biomedical Research Centre, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| | - Eva Mezeiova
- Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic.,Biomedical Research Centre, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| | - Ondrej Soukup
- Biomedical Research Centre, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| | - Jan Korabecny
- Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic.,Biomedical Research Centre, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| |
Collapse
|
3
|
Boitsov VM, Stepakov AV, Wang S, Filatov AS, Lozovskiy SV, Shmakov SV, Khoroshilova OV, Larina AG, Selivanov SI. Construction of Spiro[3-azabicyclo[3.1.0]hexanes] via 1,3-Dipolar Cycloaddition of 1,2-Diphenylcyclopropenes to Ninhydrin-Derived Azomethine Ylides. SYNTHESIS-STUTTGART 2021. [DOI: 10.1055/a-1360-9716] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
AbstractThe multi-component 1,3-dipolar cycloaddition of ninhydrin, α-amino acids (or peptides), and cyclopropenes for the synthesis of spirocyclic heterocycles containing both 3-azabicyclo[3.1.0]hexane and 2H-indene-1,3-dione motifs has been developed. This method provides easy access to 3-azabicyclo[3.1.0]hexane-2,2′-indenes with complete stereoselectivity and a high degree of atom economy under mild reaction conditions. A broad range of cyclopropenes and α-amino acids have been found to be compatible with the present protocol, which offers an opportunity to create a new library of biologically significant scaffold (3-azabicyclo[3.1.0]hexane). In addition, the сomprehensive study of mechanism of azomethine ylide formation from ninhydrin and sarcosine was performed by means of M11 density functional theory (DFT) calculations. It has been revealed that experimentally observed 1-methylspiro[aziridine-2,2′-indene]-1′,3′-dione is a kinetically controlled product of this reaction and appears to act as a 1,3-dipole precursor. This theoretical study also shed light on the main transformations of the azomethine ylide derived from ninhydrin and sarcosine such as a 1,3-dipolar cycloaddition to cyclopropene dipolarophiles, a dimerization reaction and a (1+5) electrocyclization reaction. The antitumor activity of some synthesized compounds against cervical carcinoma (HeLa) cell line was evaluated in vitro by MTS-assay.
Collapse
Affiliation(s)
- Vitali M. Boitsov
- Saint Petersburg Academic University Nanotechnology Research and Education Centre RAS
- Pavlov First Saint Petersburg State Medical University
| | | | | | | | | | - Stanislav V. Shmakov
- Saint Petersburg Academic University Nanotechnology Research and Education Centre RAS
| | | | | | | |
Collapse
|
4
|
Kazeminejad Z, Pourshamsian K, Hatamjafari F, Shiroudi A, Oliaey AR. Synthesis of Novel Triazolyl Thiourea Derivatives and Their Antibacterial Activity. RUSSIAN JOURNAL OF ORGANIC CHEMISTRY 2019. [DOI: 10.1134/s1070428019100233] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
5
|
Mousazadeh H, Milani M, Zarghami N, Alizadeh E, Safa KD. Study of the Cytotoxic and Bactericidal Effects of Sila-substituted Thioalkyne and Mercapto-thione Compounds based on 1,2,3-Triazole Scaffold. Basic Clin Pharmacol Toxicol 2017; 121:390-399. [PMID: 28613449 DOI: 10.1111/bcpt.12822] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Accepted: 05/16/2017] [Indexed: 12/16/2022]
Abstract
A series of sila-organosulphur compounds containing 1,2,3-triazole cores were screened for their cytotoxic activity on human breast cancer cell line MCF-7. Most of the tested compounds exhibited moderate-to-good activity against the cancer cells. Especially, the compound 4-((2-(trimethylsilyl)ethynylthio)methyl)-1-benzyl-1H-1,2,3-triazole (3a) from series of sila-substituted thioalkyne 1,2,3-triazoles (STATs) and the compounds 3-(1-benzyl-1H-1,2,3-triazol-4-yl)-1-mercapto-1,1-bis(trimethylsilyl)propane-2-thione (4a) and 1-mercapto-1,1-bis(trimethylsilyl)-3-(1-phenethyl-1H-1,2,3-triazol-4-yl)propane-2-thione (4e) from series of sila-substituted mercapto-thione 1,2,3-triazoles (SMTTs) exhibited promising cytotoxicity against MCF-7 with IC50 values of 35.17, 32.63 and 30.3 μg/mL, respectively. In addition, the possible mechanisms for inhibition of cell growth and induction of apoptotic cell death were explored by DAPI staining, cell cycle analysis and qRT-PCR. The synthetic compounds were evaluated for their in vitro antibacterial activities, and as a result, the most prominent effects were observed for 3e and 4e. Especially, 3e was found to be quite active against all the tested strains with the MIC values ranging from 15 to 62 μg/mL, except P. aeruginosa. The results of the time-kill assay suggested that the compound of 3e completely inhibited the growth of both gram-negative bacteria, A. baumannii, and gram-positive bacteria, S. aureus. In addition, SEM analysis confirmed morphostructural damage of the bacteria. Our findings could be applicable for developing dual-targeting anticancer/antibacterial therapeutics.
Collapse
Affiliation(s)
- Hanieh Mousazadeh
- Organosilicon Research Laboratory, Faculty of Chemistry, University of Tabriz, Tabriz, Iran
| | - Morteza Milani
- Infectious and Tropical Diseases Research Center and Department of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Nosratollah Zarghami
- Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Effat Alizadeh
- Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Kazem D Safa
- Organosilicon Research Laboratory, Faculty of Chemistry, University of Tabriz, Tabriz, Iran
| |
Collapse
|
6
|
Maramai S, Gemma S, Brogi S, Campiani G, Butini S, Stark H, Brindisi M. Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases. Front Neurosci 2016; 10:451. [PMID: 27761108 PMCID: PMC5050208 DOI: 10.3389/fnins.2016.00451] [Citation(s) in RCA: 59] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2016] [Accepted: 09/20/2016] [Indexed: 01/09/2023] Open
Abstract
D3 receptors represent a major focus of current drug design and development of therapeutics for dopamine-related pathological states. Their close homology with the D2 receptor subtype makes the development of D3 selective antagonists a challenging task. In this review, we explore the relevance and therapeutic utility of D3 antagonists or partial agonists endowed with multireceptor affinity profile in the field of central nervous system disorders such as schizophrenia and drug abuse. In fact, the peculiar distribution and low brain abundance of D3 receptors make them a valuable target for the development of drugs devoid of motor side effects classically elicited by D2 antagonists. Recent research efforts were devoted to the conception of chemical templates possibly endowed with a multi-target profile, especially with regards to other G-protein-coupled receptors (GPCRs). A comprehensive overview of the recent literature in the field is herein provided. In particular, the evolution of the chemical templates has been tracked, according to the growing advancements in both the structural information and the refinement of the key pharmacophoric elements. The receptor/multireceptor affinity and functional profiles for the examined compounds have been covered, together with their most significant pharmacological applications.
Collapse
Affiliation(s)
- Samuele Maramai
- European Research Centre for Drug Discovery and Development and Department of Biotechnology, Chemistry and Pharmacy, University of Siena Siena, Italy
| | - Sandra Gemma
- European Research Centre for Drug Discovery and Development and Department of Biotechnology, Chemistry and Pharmacy, University of Siena Siena, Italy
| | - Simone Brogi
- European Research Centre for Drug Discovery and Development and Department of Biotechnology, Chemistry and Pharmacy, University of Siena Siena, Italy
| | - Giuseppe Campiani
- European Research Centre for Drug Discovery and Development and Department of Biotechnology, Chemistry and Pharmacy, University of Siena Siena, Italy
| | - Stefania Butini
- European Research Centre for Drug Discovery and Development and Department of Biotechnology, Chemistry and Pharmacy, University of Siena Siena, Italy
| | - Holger Stark
- Institut fuer Pharmazeutische and Medizinische Chemie, Heinrich-Heine-Universitaet Duesseldorf Duesseldorf, Germany
| | - Margherita Brindisi
- European Research Centre for Drug Discovery and Development and Department of Biotechnology, Chemistry and Pharmacy, University of Siena Siena, Italy
| |
Collapse
|
7
|
Coumarin-derived azolyl ethanols: synthesis, antimicrobial evaluation and preliminary action mechanism. Sci China Chem 2016. [DOI: 10.1007/s11426-015-0351-0] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
8
|
Zhang L, Kumar KV, Rasheed S, Zhang SL, Geng RX, Zhou CH. Design, synthesis, and antibacterial evaluation of novel azolylthioether quinolones as MRSA DNA intercalators. MEDCHEMCOMM 2015. [DOI: 10.1039/c5md00186b] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Synthesis of a series of azolylthioether quinolones as a new type of potential antimicrobial agents, and preliminary interactions with MRSA DNA indicated a possible interaction mechanism.
Collapse
Affiliation(s)
- Ling Zhang
- Key Laboratory of Applied Chemistry of Chongqing Municipality
- Institute of Bioorganic & Medicinal Chemistry
- School of Chemistry and Chemical Engineering
- Southwest University
- Chongqing 400715
| | - Kannekanti Vijaya Kumar
- Key Laboratory of Applied Chemistry of Chongqing Municipality
- Institute of Bioorganic & Medicinal Chemistry
- School of Chemistry and Chemical Engineering
- Southwest University
- Chongqing 400715
| | - Syed Rasheed
- Key Laboratory of Applied Chemistry of Chongqing Municipality
- Institute of Bioorganic & Medicinal Chemistry
- School of Chemistry and Chemical Engineering
- Southwest University
- Chongqing 400715
| | - Shao-Lin Zhang
- Key Laboratory of Applied Chemistry of Chongqing Municipality
- Institute of Bioorganic & Medicinal Chemistry
- School of Chemistry and Chemical Engineering
- Southwest University
- Chongqing 400715
| | - Rong-Xia Geng
- Key Laboratory of Applied Chemistry of Chongqing Municipality
- Institute of Bioorganic & Medicinal Chemistry
- School of Chemistry and Chemical Engineering
- Southwest University
- Chongqing 400715
| | - Cheng-He Zhou
- Key Laboratory of Applied Chemistry of Chongqing Municipality
- Institute of Bioorganic & Medicinal Chemistry
- School of Chemistry and Chemical Engineering
- Southwest University
- Chongqing 400715
| |
Collapse
|
9
|
Keck TM, Burzynski C, Shi L, Newman AH. Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design. ADVANCES IN PHARMACOLOGY 2014; 69:267-300. [PMID: 24484980 DOI: 10.1016/b978-0-12-420118-7.00007-x] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
The dopamine D3 receptor is a target of pharmacotherapeutic interest in a variety of neurological disorders including schizophrenia, restless leg syndrome, and drug addiction. The high protein sequence homology between the D3 and D2 receptors has posed a challenge to developing D3 receptor-selective ligands whose behavioral actions can be attributed to D3 receptor engagement, in vivo. However, through primarily small-molecule structure-activity relationship (SAR) studies, a variety of chemical scaffolds have been discovered over the past two decades that have resulted in several D3 receptor-selective ligands with high affinity and in vivo activity. Nevertheless, viable clinical candidates remain limited. The recent determination of the high-resolution crystal structure of the D3 receptor has invigorated structure-based drug design, providing refinements to the molecular dynamic models and testable predictions about receptor-ligand interactions. This chapter will highlight recent preclinical and clinical studies demonstrating potential utility of D3 receptor-selective ligands in the treatment of addiction. In addition, new structure-based rational drug design strategies for D3 receptor-selective ligands that complement traditional small-molecule SAR to improve the selectivity and directed efficacy profiles are examined.
Collapse
Affiliation(s)
- Thomas M Keck
- Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program, Baltimore, Maryland, USA
| | - Caitlin Burzynski
- Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program, Baltimore, Maryland, USA
| | - Lei Shi
- Department of Physiology and Biophysics and Institute for Computational Biomedicine, Weill Cornell Medical College, New York, USA
| | - Amy Hauck Newman
- Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program, Baltimore, Maryland, USA.
| |
Collapse
|
10
|
Ye N, Neumeyer JL, Baldessarini RJ, Zhen X, Zhang A. Update 1 of: Recent Progress in Development of Dopamine Receptor Subtype-Selective Agents: Potential Therapeutics for Neurological and Psychiatric Disorders. Chem Rev 2013; 113:PR123-78. [DOI: 10.1021/cr300113a] [Citation(s) in RCA: 75] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Na Ye
- CAS Key Laboratory of Receptor Research, and Synthetic Organic & Medicinal Chemistry Laboratory (SOMCL), Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China 201203
| | - John L. Neumeyer
- Medicinal Chemistry Laboratory,
McLean Hospital, Harvard Medical School, Massachusetts 02478, United States
| | | | - Xuechu Zhen
- Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China 215123
| | - Ao Zhang
- CAS Key Laboratory of Receptor Research, and Synthetic Organic & Medicinal Chemistry Laboratory (SOMCL), Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China 201203
| |
Collapse
|
11
|
Wang Q, Zhang J, Damu GLV, Wan K, Zhang H, Zhou C. Synthesis and biological activities of thio-triazole derivatives as novel potential antibacterial and antifungal agents. Sci China Chem 2012. [DOI: 10.1007/s11426-012-4602-1] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
12
|
Thompson MJ, Louth JC, Ferrara S, Sorrell FJ, Irving BJ, Cochrane EJ, Meijer AJHM, Chen B. Structure-activity relationship refinement and further assessment of indole-3-glyoxylamides as a lead series against prion disease. ChemMedChem 2011; 6:115-30. [PMID: 21154498 DOI: 10.1002/cmdc.201000383] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Structure-activity relationships within the indole-3-glyoxylamide series of antiprion agents have been explored further, resulting in discovery of several new compounds demonstrating excellent activity in a cell line model of prion disease (EC₅₀ <10 nM). After examining a range of substituents at the para-position of the N-phenylglyoxylamide moiety, five-membered heterocycles containing at least two heteroatoms were found to be optimal for the antiprion effect. A number of modifications were made to probe the importance of the glyoxylamide substructure, although none were well tolerated. The most potent compounds did, however, prove largely stable towards microsomal metabolism, and the most active library member cured scrapie-infected cells indefinitely on administration of a single treatment. The present results thereby confirm the indole-3-glyoxylamides as a promising lead series for continuing in vitro and in vivo evaluation against prion disease.
Collapse
Affiliation(s)
- Mark J Thompson
- Department of Chemistry, University of Sheffield, Brook Hill, UK
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Micheli F. Recent Advances in the Development of Dopamine D3 Receptor Antagonists: a Medicinal Chemistry Perspective. ChemMedChem 2011; 6:1152-62. [DOI: 10.1002/cmdc.201000538] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2011] [Indexed: 11/08/2022]
|
14
|
Micheli F, Arista L, Bertani B, Braggio S, Capelli AM, Cremonesi S, Di-Fabio R, Gelardi G, Gentile G, Marchioro C, Pasquarello A, Provera S, Tedesco G, Tarsi L, Terreni S, Worby A, Heidbreder C. Exploration of the Amine Terminus in a Novel Series of 1,2,4-Triazolo-3-yl-azabicyclo[3.1.0]hexanes as Selective Dopamine D3 Receptor Antagonists. J Med Chem 2010; 53:7129-39. [DOI: 10.1021/jm100832d] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Fabrizio Micheli
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Luca Arista
- Novartis Institute Research, Basel, Switzerland
| | - Barbara Bertani
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Simone Braggio
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Anna Maria Capelli
- Molecular Discovery Research
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Susanna Cremonesi
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Romano Di-Fabio
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Giacomo Gelardi
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Gabriella Gentile
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Carla Marchioro
- Molecular Discovery Research
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Alessandra Pasquarello
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Stefano Provera
- Molecular Discovery Research
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Giovanna Tedesco
- Molecular Discovery Research
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Luca Tarsi
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Silvia Terreni
- Neurosciences Centre of Excellence
- GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | | | | |
Collapse
|
15
|
Micheli F, Hamprecht D, Bonanomi G, Di Fabio R, Donati D, Gentile G, Heidbreder C, Prandi A, Tarsi L, Terreni S. [3-Azabicyclo[3.1.0]hex-1-yl]phenyl-benzenesulfonamides as selective dopamine D3 antagonists. Bioorg Med Chem Lett 2010; 20:5491-4. [DOI: 10.1016/j.bmcl.2010.07.073] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2010] [Revised: 07/15/2010] [Accepted: 07/16/2010] [Indexed: 10/19/2022]
|
16
|
Micheli F, Andreotti D, Braggio S, Checchia A. A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D3 antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template. Bioorg Med Chem Lett 2010; 20:4566-8. [DOI: 10.1016/j.bmcl.2010.06.018] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2010] [Revised: 05/31/2010] [Accepted: 06/02/2010] [Indexed: 11/29/2022]
|